New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.1
Lead researcher, Patrick Le Goux of the Hôpitaux Universitaires Paris Ile-de-France Ouest, France, commented, "while PRP injections were shown to have no inherent benefit in the treatment of epicondylitis, what is exciting is that pain scores in both treatment groups decreased significantly over the course of the trial. The healing process is stimulated by the echo-guided injection of a substance and/or by the own effect of the needle (needling); the injections stimulate the process of tendon repair through an irritation effect, a technique known as prolotherapy."
Epicondylitis is a painful condition that occurs when the tendons in the elbow are overworked, usually by repetitive motions of the wrist and arm. In lateral epicondylitis (also referred to as tennis elbow), the pain occurs primarily where the tendons of the forearm muscles attach to the bone on the outside of the elbow2 and medial epicondylitis (also referred to as golfer's elbow) where the tendons attach to the bone on the inside of the elbow. The pain of both conditions may also spread to the forearm and wrist.3
Although a large number of treatments – including physiotherapy, corticosteroid injections, and non-steroidal anti-inflammatory drugs – are used to treat epicondylitis, there is no consensus on which is the most effective.4 Recently, local injections of growth factors containing platelet-rich plasma (PRP) were proposed as a new therapeutic technique for boosting tendon repair,5 with ultrasound guidance of the intra-tendinous injections used to optimise the procedure.6
In this latest study, patients with recent onset epicondylitis (pain ≤3 months), confirmed by MRI and/or ultrasound, were treated with two ultrasound-guided injections at 4 week intervals. Patients received either PRP (ACP®, Arthrex) or saline solution and were monitored by an independent clinical evaluator, blinded to the treatment at baseline, one, three, six and 12 months.
The primary evaluation criterion was the relative improvement from baseline to six months in pain score (PS) on the visual analogue scale (0-10). The secondary criteria was the assessment of pain (yes/no) on isometric contraction of the second radial and of the muscle of the posterior forearm (extensor digitorum communis), the Roles-Maudsley score* (1-4), the proportion of asymptomatic patients (PS ≤1) at six and 12 months follow-up and the proportion of patients with persistent pain (PS >2) at 12 months follow-up. Fifty patients were included in the study, 25 in each arm, but only 22 in both groups completed the follow up at 12 months.
At a six-month follow-up, no statistically significant difference was found between the groups for mean relative improvement in pain (ACP 54.7% vs. control 63.6%; p=0.24) and no statistically significant difference was found for the secondary criteria. In the two groups, the pain score decreased significantly between two consecutive visits from 6.8±0.8 (PRP) and 7±1 (control) at baseline to 2.5±1.6 (PRP) and 2.1±1.6 (control) at 6 months and 1.65±1.5 (PRP) and 1.8±2.1 (control) at 12 months. At six months, 34% of all patients were asymptomatic; 66% were asymptomatic at one year. The proportion of patients with persistent pain at 12 months was 23.8% in both groups. No adverse effects were observed.
Abstract Number: OP0013
NOTES TO EDITORS: For further information on this study, or to request an interview with the study lead, please contact us via: EULAR congress
Press Office: Room 104, Palais des congrčs de Paris
Onsite tel: +44 (0) 7880 173209
The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.
* The Roles-Maudsley score is a subjective 4-point patient assessment of pain and limitations of activity (1 = excellent result with no symptoms following treatment; 2 = significant improvement from pre-treatment; 3 = patient somewhat improved; 4 = poor, symptoms identical or worse than pre-treatment).
EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.
With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 17 health professionals associations and 26 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care.
EULAR 2014 is set to be the biggest rheumatology event in Europe with almost 14,000 scientists, physicians, allied health professionals and related audiences in attendance from 130 countries. Over the course of the congress there will be 302 oral and 1,806 poster abstract presentations, 155 sessions, 725 lectures, 33 poster tours with 421 invited speakers.
To find out more about the activities of EULAR, visit: http://www.eular.org
1 Le Goux P, Montalvan B, Leparc JM et al. Treatment Of Epicondylitis By Ultrasound-Guided Local Injections Of Autologous Conditioned Plasma (Acp®): A Double-Blind Placebo-Controlled Randomized Clinical Trial With 1-Year Follow-Up. EULAR 2014; Paris: Abstract OP0013
2 Mayo Clinic. Diseases and Conditions: Tennis elbow: Definition. http://www.mayoclinic.org/diseases-conditions/tennis-elbow/basics/definition/con-20043041 [Accessed 05/06/2014]
3 Mayo Clinic. Diseases and Conditions: Golfer's elbow: Definition. http://www.mayoclinic.org/diseases-conditions/golfers-elbow/basics/definition/con-20027964 [Accessed 05/06/2014]
4 Olaussen M, Holmedal O, Lindbaek M et al. Treating lateral epicondylitis with corticosteroid injections or non-electrotherapeutical physiotherapy: a systematic review. BMJ Open 2013;3:e003564 doi:10.1136/bmjopen-2013-003564
5 Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010; 38(2): 255-62
6 Chiavaras MM, Jacobson JA, Semin Musculoskelet Radiol 2013; 17(1): 85-90
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.